The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.
© Thomson Reuters 2020.Inovio signs COVID-19 vaccine manufacturing deal with Japan's Kaneka
TOKYO©2024 GPlusMedia Inc.
The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.
© Thomson Reuters 2020.
7 Comments
Login to comment
Samit Basu
Why did Kaneka sign up for a Korean vaccine trial?
Just as BioNTech(Pfizer vaccine developer) is a Turkish-based company based in Germany, Inovio is a Korean-based company based in America.
Jairam Amrith
All this talk of foreign vaccines, but what's the status of Japan's home vaccine supposedly being developed by Osaka University in collaboration with AnGes MG Biotech of Osaka?
After a flurry of announcements in mid-year, which propelled AnGes stock up at a meteoric rate, there has been dead silence, and AnGes' stock price has plummeted. Was it all just an announcement to make a few insiders rich ? If so, it's particularly egregious, and the authorities should take action.
1glenn
Nationalistic pride should not come into the discussion of saving lives.
proxy
Ivermectin anyone?
albaleo
What do you mean by Turkish-based?
What do you mean by Korean-based?
Nihonview
"Why did Kaneka sign up for a Korean vaccine trial?
Just as BioNTech(Pfizer vaccine developer) is a Turkish-based company based in Germany, Inovio is a Korean-based company based in America."
Total BS. Inovio is American company. The majority of shares are own by American Institutions. Just because its CEO is a Korean--American does not make it a Korean company. The same goes of BioNtech. Its a German company with a Turk as CEO.
Nihonview
"Why did Kaneka sign up for a Korean vaccine trial?"
It did not. It entered into a manufacturing agreement with Invio. Most Biotech companies are small and they lack the manufacturing capacity to produce medicine on a large scale, so they farm out the production to other companies.